Drugs / Mycobacterial Cell-Wall DNA Complex
Mycobacterial Cell-Wall DNA Complex
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00406068 | Nov 2006 → Jul 2011 | urinary bladder neoplasm | Bioniche Life Sciences Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01284205 | Jan 2010 → Feb 2014 | urinary bladder cancer | Bioniche Life Sciences Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycobacterial Cell-Wall DNA Complex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01284205 ↗ |
| Known as | EN3348 | “The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are...” NCT01284205 ↗ |
| Known as | MCC | “The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are...” NCT01284205 ↗ |
| Known as | MCC - Urocidin | “MCC - Urocidin” NCT00406068 ↗ |
| Route | Other | “8 mg/50 mL (sterile WFI) Intravesical Administration” NCT01284205 ↗ |